Cheng-Jen Chiu

Dr. Cheng-Jen Chiu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Ssu-Hsien LeeSsu-Hsien Lee
Ssu-Hsien Lee
BTBor-Yuan Tseng
Bor-Yuan Tseng
MWMeng-Chien Wu
Meng-Chien Wu
JWJen-Hung Wang
Jen-Hung Wang
CCCheng-Jen Chiu
Cheng-Jen Chiu

28 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Ssu-Hsien LeeSsu-Hsien Lee
Ssu-Hsien Lee
BTBor-Yuan Tseng
Bor-Yuan Tseng
Jen-Hung WangJen-Hung Wang
Jen-Hung Wang
CCCheng-Jen Chiu
Cheng-Jen Chiu
Objectives: To evaluate the efficacy of myopia prevention methods in children without pre-existing myopia. Methods: A network meta-analysis was conducted following the PRISMA-NMA guidelines. Comprehensive searches were performed in PubMed, Embase, and Cochrane CENTRAL databases. The analysis focused on randomized controlled trials evaluating myopia prevention strategies in children without prior myopia. Primary outcomes included annual changes in refraction and axial length, while secondary outcomes encompassed myopia incidence and adverse events. Effect sizes were reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CIs). Data synthesis utilized a random-effects model under a frequentist framework, with intervention efficacy ranked by P-scores. Study quality was assessed using the Cochrane risk-of-bias tool, and robustness was ensured via sensitivity and consistency analyses. Results: Low-level red light therapy and low-dose atropine were the most effective interventions for reducing refractive progression (MD: 0.48 D, 95% CI: 0.38–0.59 D; MD: 0.33 D, 95% CI: 0.23–0.43 D) and axial elongation (MD: −0.23 mm, 95% CI: −0.27 to −0.19 mm; MD: −0.12 mm, 95% CI: −0.16 to −0.08 mm). In addition, both significantly lowered myopia incidence (RR: 0.59, 95% CI: 0.45–0.79; RR: 0.55, 95% CI: 0.41–0.75). Outdoor activities and myopia awareness programs demonstrated moderate efficacy. Adverse events, including photophobia and dry eyes, were minor and self-limiting, with no serious complications reported. Conclusions: Low-level red light therapy and low-dose atropine are the most effective, generally safe strategies for preventing myopia in at-risk children without myopia, while a non-invasive approach, outdoor activities, provides moderate benefits.